Palvella Therapeutics Inc

Idorsia Pharmaceuticals US Inc., headquartered in Radnor, Pennsylvania, is dedicated to expanding access to transformative treatments for patients through its innovative research and clinical development efforts. With subsidiaries across North America, Europe, and Asia, Idorsia focuses on drug discovery, development, and commercial operations to address various target diseases, including insomnia and hypertension. As a part of Idorsia Ltd., the company emphasizes the importance of patient well-being by leveraging its team's expertise to deliver pioneering therapies. Committed to regulatory compliance and market operations in multiple countries, Idorsia aims to enhance healthcare solutions worldwide. Generated from the website

CSL Behring is one of the leading providers of plasma protein biotherapeutic products in the world. It is a pharmaceutical company engaged in the research and development of life-saving biotherapies for the treatment of coagulation disorders, such as hemophilia and von Willebrand diseases. The company additionally manufactures a variety of medicines and drugs for the treatment of immune deficiencies, genetic emphysema, sepsis, severe burns, wounds and heomolytic diseases. It also provides medicines for transplantation, coagulation, immunology and critical care applications. The company supplies products under the Cytogam, Helixate, Humate-P, Monoclate-P, Mononine, Stimate, AlbuRx, Albuminar and Vivaglobin brands. It offers sales, marketing, distribution, online ordering and customer support services. The company maintains CSL Plasma, which is a plasma collection network that operates throughout the United States and Germany. CSL Behring is a part of CSL Limited, which is an Australia-based company that supplies sera and vaccines.

Trevena, Inc is an innovative biopharmaceutical company based in Chesterbrook, PA, dedicated to developing groundbreaking medicines for patients with central nervous system (CNS) disorders. Their pipeline includes one FDA-approved product, OLINVYK oliceridine injection, and three differentiated investigational drug candidates, targeting various therapeutic areas such as acute pain, diabetic neuropathic pain, epilepsy, acute migraine, and opioid use disorder. With a focus on targeted and innovative CNS therapies, Trevena's pipeline is built on Nobel Prize-winning research and aims to address the critical needs of patients. Their commitment to innovation and patient care drives their mission to deliver effective treatments for CNS disorders.Generated from the website